| Date | Title | Description |
| 10.05.2024 | iTeos Therapeutics Announces $120 Million Registered Direct Offering | - |
| 10.05.2024 | iTeos Therapeutics Announces $120 Million Registered Direct Offering | - Led by existing investors RA Capital Management and Boxer Capital
- Purchase price of $17.50 represents a premium of approximately 44% to last close
- Further strengthens balance sheet with pro forma cash position of $715 million, extendi... |
| 09.03.2024 | iTeos: A Financial Success Story | iTeos, a biotechnology company, recently released its financial results for the fourth quarter and full year of 2023. The company's progress and future plans are highlighted in this article, showcasing its growth and success in the industry... |
| 07.03.2024 | iTeos fait le point sur ses activités et publie ses résultats financiers pour le quatrième trimestre et l’exercice 2023 | - |
| 06.03.2024 | La spécialiste en oncologie Jill DeSimone rejoint le Conseil d’administration d’iTeos | - |
| 06.03.2024 | iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors | - |
| 06.03.2024 | iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates | - |
| 05.03.2024 | iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 | - |
| 05.03.2024 | iTeos présentera les données précliniques d’EOS-984, premier médicament de sa catégorie ciblant l’ENT1, lors de l'édition 2024 du congrès annuel de l’Association américaine pour la recherche sur le ca... | - |
| 01.04.2020 | iTeos Therapeutics Closes $125M Series B2 |
CAMBRIDGE, MA, iTeos Therapeutics announced the closing of an oversubscribed $125M Series B2 financing, co-led by RA Capital Management and Boxer Capital.
>> Click here for more funding data on iTeos Therapeutics
>> To expor... |
| 01.04.2020 | iTeos Therapeutics Raises $125M in Series B2 Funding | iTeos Therapeutics Inc., a Cambridge, MA and Gosselies, Belgium – based clinical-stage biotechnology company developing innovative cancer immunotherapies, closed a $125m Series B2 financing.
The round was co-led by RA Capital Management and... |
| 01.04.2020 | iTeos Therapeutics Closes $125 Million Series B2 Financing | - |
| 30.01.2020 | iTeos Therapeutics Awarded €15 Million in Non-Dilutive Funding by the Walloon Region | - |
| 21.06.2018 | iTeos Therapeutics Closes $75M Series B Financing | iTeos Therapeutics SA, a Gosselies, Belgium – based biotechnology company developing novel cancer immunotherapies, completed a $75m (€64m) Series B financing.
The round was led by MPM Capital, with participation from new investors HBM Partn... |
| 21.06.2018 | Term Sheet — Thursday, June 21 | GLOBAL DOMINATION
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
Chain previously raised more than $43 million in venture funding from investors including Khosla Ventures, RRE Ventures, Bloc... |
| 20.06.2018 | ITeos raises $75M to trial immuno-oncology drugs | iTeos Therapeutics has raised $75 million (€64 million) to take two immuno-oncology assets into the clinic. The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year while expanding... |
| 20.06.2018 | ITeos raises $75M to trial immuno-oncology drugs | iTeos Therapeutics has raised $75 million (€64 million) to take two immuno-oncology assets into the clinic. The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine A2A antagonist later this year while expanding... |
| 20.06.2018 | MPM Leads $75 Million Series B Financing of iTeos Therapeutics | - |
| 07.12.2015 | iTeos Therapeutics Receives €2.94M Grant | iTeos Therapeutics SA, a Gosselies, Belgium-based drug discovery company for immunomodulators, received a €2.94m non-dilutive funding.
The Walloon Region of Belgium provided the grant.
The company intends to use the funds to expand its prec... |
